Microinvasive Breast Carcinoma with Extensive Involvement of Level III Axillary Lymph Nodes: A Case Report

Japanese Journal of Clinical Oncology

Volumn 28, Issue 1, 1998, Pages 47-49

  Fujii, Kimihito ^a   Fukutomi, Takashi ^a   Tsuda, Hitoshi ^a   Akashi Tanaka, Sadako ^a   Nanasawa, Takeshi ^a   Kanai, Yae ^a   Muramatsu, Yukio ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Ductal carcinoma in situ with microinvasion; Lymph node dissection; Lymph node metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

ADULT; ARTICLE; AXILLA; BREAST TUMOR; CANCER INVASION; CASE REPORT; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; MASTECTOMY; METABOLISM; METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, RADICAL; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031611768     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.1.47     Document Type: Article

References (12)

1. Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer 1991;67:1498-503.
2. Solin L, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992;23:961-8.
3. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;125:1298-302.
4. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 1990;65:1794-800.
5. Iwaya K, Tsuda H, Hirade H, Tamaki K, Tamakuma S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-40.
6. Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer Its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990;81:327-32.
7. Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma. Analysis of presentation, pathologic findings and outcome of disease. Arch Surg 1986;121:1303-7.
8. Enjoji M, Sakamoto G, Toyoshima S, Hirota T, Wada A, Yamamoto H, et al. Invasive ductal carcinoma with a predominant intraductal component of the breast: A joint study. Jpn J Breast Cancer 1990;5:253-8 (in Japanese with English abstract).
9. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 1993;84:394-401.
10. Schwartz GF, Patchefsky AS, Finklestein SD, Shon SH, Prestiptno A, Feig SA, et al. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment Arch Surg 1989;124:29-32.
11. Patchefsky AS, Schwartz GF, Finkelstein SD, Prestipino A, Shon SE, Singer JS, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
12. Kinne DW, Petrek JA, Osborne MP, Fracchia AA, DePalo AA, Rosen PP. Breast carcinoma in situ. Arch Surg 1989;124:33-6.